id:"swepub:oai:gup.ub.gu.se/268956"
Search: id:"swepub:oai:gup.ub.gu.se/268956" > Anti-Leukemic Prope...
- 1 of 1
- Previous record
- Next record
- To hitlist
Anti-Leukemic Properties of Histamine in Monocytic Leukemia: The Role of NOX2
-
- Kiffin, Roberta (author)
- Gothenburg University,Göteborgs universitet,Sahlgrenska Cancer Center
-
- Grauers Wiktorin, Hanna, 1990 (author)
- Gothenburg University,Göteborgs universitet,Sahlgrenska Cancer Center
-
- Nilsson, Malin S. (author)
- Gothenburg University,Göteborgs universitet,Sahlgrenska Cancer Center
- show more...
- show less...
- (creator_code:org_t)
- 2018-06-18
- 2018
- English.
- In: Frontiers in Oncology. - : Frontiers Media SA. - 2234-943X. ; 8
- Journal article (peer-reviewed)
Abstract
Subject headings
Close
- In patients with acute myeloid leukemia (AML), treatment with histamine dihydrochloride (HDC) and low-dose IL-2 (HDC/ IL-2) in the post-chemotherapy phase has been shown to reduce the incidence of leukemic relapse. The clinical benefit of HDC/ IL-2 is pronounced in monocytic forms of AML, where the leukemic cells express histamine type 2 receptors (H2R) and the NAPDH oxidase-2 (NOX2). HDC ligates to H(2)Rs to inhibit NOX2-derived formation of reactive oxygen species, but details regarding the anti-leukemic actions of HDC remain to be elucidated. Here, we report that human NOX2(+) myelomonocytic/monocytic AML cell lines showed increased expression of maturation markers along with reduced leukemic cell proliferation after exposure to HDC in vitro. These effects of HDC were absent in corresponding leukemic cells genetically depleted of NOX2 (NOX2(-/-)). We also observed that exposure to HDC altered the expression of genes involved in differentiation and cell cycle progression in AML cells and that these effects required the presence of NOX2. HDC promoted the differentiation also of primary monocytic, but not non-monocytic, AML cells in vitro. In a xenograft model, immunodeficient NOG mice were inoculated with wild-type or NOX2(-/-) human monocytic AML cells and treated with HDC in vivo. The administration of HDC reduced the in vivo expansion of NOX2(+/+), but not of NOX2(-/-) human monocytic AML cells. We propose that NOX2 may be a conceivable target in the treatment of monocytic AML.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Keyword
- histamine
- NAPDH oxidase
- NOX2
- acute myeloid leukemia
- acute monocytic leukemia
- acute myelomonocytic leukemia
- acute myeloid-leukemia
- reactive oxygen metabolites
- low-dose
- interleukin-2
- nadph-oxidase activity
- cell-line
- remission maintenance
- human neutrophils
- nk cells
- expression
- differentiation
- Oncology
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
- Frontiers in Oncology (Search for host publication in LIBRIS)
To the university's database
- 1 of 1
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Kiffin, Roberta
- Grauers Wiktorin ...
- Nilsson, Malin S ...
- Aurelius, Johan, ...
- Aydin, Ebru
- Lenox, Brianna
- show more...
- Nilsson, Jonas A ...
- Ståhlberg, Ander ...
- Bergh Thorén, Fr ...
- Hellstrand, Kris ...
- Martner, Anna, 1 ...
- show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Clinical Medicin ...
- and Cancer and Oncol ...
- Articles in the publication
- Frontiers in Onc ...
- By the university
- University of Gothenburg
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
